KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Invested Capital (2016 - 2025)

Neogenomics (NEO) has disclosed Invested Capital for 16 consecutive years, with $836.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital fell 7.29% year-over-year to $836.6 million, compared with a TTM value of $836.6 million through Dec 2025, down 7.29%, and an annual FY2025 reading of $836.6 million, down 7.29% over the prior year.
  • Invested Capital was $836.6 million for Q4 2025 at Neogenomics, roughly flat from $838.3 million in the prior quarter.
  • Across five years, Invested Capital topped out at $1.1 billion in Q2 2021 and bottomed at $836.6 million in Q4 2025.
  • Average Invested Capital over 5 years is $962.7 million, with a median of $944.5 million recorded in 2023.
  • The sharpest move saw Invested Capital soared 75.53% in 2021, then fell 10.93% in 2022.
  • Year by year, Invested Capital stood at $1.1 billion in 2021, then decreased by 9.95% to $998.0 million in 2022, then dropped by 5.66% to $941.5 million in 2023, then dropped by 4.16% to $902.3 million in 2024, then fell by 7.29% to $836.6 million in 2025.
  • Business Quant data shows Invested Capital for NEO at $836.6 million in Q4 2025, $838.3 million in Q3 2025, and $854.0 million in Q2 2025.